Christopher Heery, MD

Board Member

Dr. Christopher Heery is the Chief Medical Officer at Arcellx, where he is responsible for medical oversight, clinical strategy, medical affairs, and regulatory strategy. Prior to Arcellx, Chris was the Chief Medical Officer of Precision BioSciences and Bavarian Nordic. At Precision, he oversaw the clinical development of one of the first allogeneic CAR T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. While at Bavarian Nordic, Chris oversaw clinical development programs for its immune-oncology and infectious disease vaccine portfolio. Before transitioning to industry, Chris was head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI). At NCI, he was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer.

Chris holds a BA in English Literature from Duke University and an MD from East Carolina University Brody School of Medicine. He is board certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago.